BioVaxys Technology Corp. and Adiverna LLC have entered a research agreement to develop mRNA-based vaccines for rabies, leptospirosis, feline infectious peritonitis, and other diseases affecting dogs and cats. This collaboration combines BioVaxys' DPX immune educating platform with Adiverna's artificial intelligence-designed mRNA sequences, targeting a market where no mRNA vaccines are currently approved for companion animals.
The partnership's importance lies in addressing significant limitations of traditional veterinary vaccines. Current vaccines for companion animals typically provide protection for one to three years, with rabies vaccines usually lasting one year before requiring boosters. The global rabies veterinary vaccines market is valued at US$785 million in 2024 and projected to reach approximately US$1.1 billion by 2030, according to Research & Markets data from January 20, 2025. The broader dog vaccine market was valued at approximately $2.10 billion in 2025, while the feline vaccines sector is projected to reach USD 3.28 billion by 2034 from USD 1.77 billion in 2025, as reported by Fortune Business Insights in February 2026.
Adiverna's proprietary AI technology represents a breakthrough approach in veterinary healthcare. The company's platform uses machine learning algorithms and advanced bioinformatics to analyze extensive datasets, identifying and predicting the most effective mRNA sequences that code for protective broadly cross-neutralizing antigens. This AI-guided design offers significant dose-sparing potential, reducing the amount of vaccine required while still eliciting robust immune responses. Adiverna's technology is detailed on their website at https://www.adiverna.com.
BioVaxys' DPX platform addresses challenges faced by traditional vaccine formulations. Unlike emulsion-based vaccines that can spill from injection sites leading to systemic inflammatory responses, or lipid nanoparticles that show instability under in vivo conditions, the DPX platform presents antigens using a novel non-systemic mechanism. This approach forces active uptake by immune cells and delivery into lymphatic nodes, mimicking the natural function of the immune system. Proof-of-concept studies demonstrate that DPX provides enhanced stability of packaged mRNA and attracts unique subsets of antigen presenting cells to injection sites.
The potential impact of this collaboration extends beyond veterinary applications. As noted by BioVaxys President Kenneth Kovan, demonstrated in vivo proof of concept of DPX mRNA formulations will further partnering discussions for human therapeutic applications. The technology offers advantages including non-systemic depot delivery, micro-dosing, excellent shelf-life stability, and clinically demonstrated efficacy and safety in both human and animal health use.
Market growth is driven by mandatory pet vaccinations, increasing disease awareness, and rising pet ownership globally. North America currently dominates the companion animal vaccination market, while the Asia/Pacific region experiences rapid growth due to increasing vaccination campaigns in countries like India and China, according to DelveInsight's Veterinary Vaccines Market Insights from 2024. The collaboration between BioVaxys and Adiverna could establish new standards for vaccine efficacy and safety in veterinary medicine while creating potential pathways for human medical applications.
